Loading…
Identification of potential complementary serum biomarkers to differentiate prostate cancer from benign prostatic hyperplasia using gel‐ and lectin‐based proteomics analyses
Diagnosis of prostate cancer (PCa) is currently much reliant on the invasive and time‐consuming transrectal ultrasound‐guided biopsy of the prostate gland, particularly in light of the inefficient use of prostate‐specific antigen as its biomarker. In the present study, we have profiled the sera of p...
Saved in:
| Published in: | Electrophoresis 2012-07, Vol.33 (12), p.1855-1862 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3288-c67d28a75ede61b8b609f45cfb2215791a72812d16aa70c1c13eda0d24f54e673 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3288-c67d28a75ede61b8b609f45cfb2215791a72812d16aa70c1c13eda0d24f54e673 |
| container_end_page | 1862 |
| container_issue | 12 |
| container_start_page | 1855 |
| container_title | Electrophoresis |
| container_volume | 33 |
| creator | Jayapalan, Jaime J. Ng, Keng L. Razack, Azad H. A. Hashim, Onn H. |
| description | Diagnosis of prostate cancer (PCa) is currently much reliant on the invasive and time‐consuming transrectal ultrasound‐guided biopsy of the prostate gland, particularly in light of the inefficient use of prostate‐specific antigen as its biomarker. In the present study, we have profiled the sera of patients with PCa and benign prostatic hyperplasia (BPH) using the gel‐ and lectin‐based proteomics methods and demonstrated the significant differential expression of apolipoprotein AII, complement C3 beta chain fragment, inter‐alpha‐trypsin inhibitor heavy chain 4 fragment, transthyretin, alpha‐1‐antitrypsin, and high molecular weight kininogen (light chain) between the two groups of patients’ samples. Our data are suggestive of the potential use of the serum proteins as complementary biomarkers to effectively discriminate PCa from BPH, although this requires further extensive validation on clinically representative populations. |
| doi_str_mv | 10.1002/elps.201100608 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1272741488</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1272741488</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3288-c67d28a75ede61b8b609f45cfb2215791a72812d16aa70c1c13eda0d24f54e673</originalsourceid><addsrcrecordid>eNqFkc1u1DAUhS0EokNhyxJ5ySaD_xI7S1QVWmkkkIB15NjXg8GJg52oyo5H4FX6SjwJDtN225V9fb9zZJ2D0GtK9pQQ9g7ClPeM0DI0RD1BO1ozVrFG8adoR6jkFVG8PkMvcv5BCBGtEM_RGWNSECHFDt1eWxhn77zRs48jjg5Pcd6edMAmDlOAoUw6rThDWgbc-zjo9BNSxnPE1jsH6T8-A55SzPN2MXo0kLBLsQhg9MfxfucN_r5OkKags9d4yX484iOEv7__YD1aHMDMfixTrzPYTTVDHLzJZavDmiG_RM-cDhle3Z3n6NuHy68XV9Xh08fri_eHynCmVGUaaZnSsgYLDe1V35DWidq4njFay5ZqyRRlljZaS2KooRysJpYJVwtoJD9Hb0--5Q-_FshzN_hsIAQ9QlxyR5ksKVKh1OMoYUzxtlWb6_6EmpJHTuC6KfkS6Fqgbmu02xrtHhotgjd33ks_gH3A7yssgDgBNz7A-ohdd3n4_EUwrvg_G4qzoA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1022839987</pqid></control><display><type>article</type><title>Identification of potential complementary serum biomarkers to differentiate prostate cancer from benign prostatic hyperplasia using gel‐ and lectin‐based proteomics analyses</title><source>Wiley</source><creator>Jayapalan, Jaime J. ; Ng, Keng L. ; Razack, Azad H. A. ; Hashim, Onn H.</creator><creatorcontrib>Jayapalan, Jaime J. ; Ng, Keng L. ; Razack, Azad H. A. ; Hashim, Onn H.</creatorcontrib><description>Diagnosis of prostate cancer (PCa) is currently much reliant on the invasive and time‐consuming transrectal ultrasound‐guided biopsy of the prostate gland, particularly in light of the inefficient use of prostate‐specific antigen as its biomarker. In the present study, we have profiled the sera of patients with PCa and benign prostatic hyperplasia (BPH) using the gel‐ and lectin‐based proteomics methods and demonstrated the significant differential expression of apolipoprotein AII, complement C3 beta chain fragment, inter‐alpha‐trypsin inhibitor heavy chain 4 fragment, transthyretin, alpha‐1‐antitrypsin, and high molecular weight kininogen (light chain) between the two groups of patients’ samples. Our data are suggestive of the potential use of the serum proteins as complementary biomarkers to effectively discriminate PCa from BPH, although this requires further extensive validation on clinically representative populations.</description><identifier>ISSN: 0173-0835</identifier><identifier>ISSN: 1862-8346</identifier><identifier>EISSN: 1522-2683</identifier><identifier>DOI: 10.1002/elps.201100608</identifier><identifier>PMID: 22740474</identifier><language>eng</language><publisher>Germany</publisher><subject>Aged ; Apolipoprotein A-II ; Benign ; Benign prostatic hyperplasia ; Biomarker ; biomarkers ; Biomarkers, Tumor - blood ; Biomarkers, Tumor - chemistry ; Biopsy ; Blood Proteins - analysis ; Blood Proteins - chemistry ; Blood Proteins - metabolism ; Complement component C3 ; Data processing ; Diagnosis, Differential ; Electrophoresis, Gel, Two-Dimensional ; Glycoproteins - blood ; Glycoproteins - chemistry ; Glycoproteins - metabolism ; Humans ; Hyperplasia ; Invasiveness ; kininogens ; Lectin ; Lectins - metabolism ; Light chains ; Male ; Middle Aged ; Prostate cancer ; prostate-specific antigen ; Prostatic Hyperplasia - blood ; Prostatic Neoplasms - blood ; Proteomics ; Proteomics - methods ; Serum proteins ; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization ; Therapeutic applications ; transthyretin</subject><ispartof>Electrophoresis, 2012-07, Vol.33 (12), p.1855-1862</ispartof><rights>2012 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim</rights><rights>2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3288-c67d28a75ede61b8b609f45cfb2215791a72812d16aa70c1c13eda0d24f54e673</citedby><cites>FETCH-LOGICAL-c3288-c67d28a75ede61b8b609f45cfb2215791a72812d16aa70c1c13eda0d24f54e673</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Felps.201100608$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Felps.201100608$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,786,790,27957,27958,50923,51032</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22740474$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jayapalan, Jaime J.</creatorcontrib><creatorcontrib>Ng, Keng L.</creatorcontrib><creatorcontrib>Razack, Azad H. A.</creatorcontrib><creatorcontrib>Hashim, Onn H.</creatorcontrib><title>Identification of potential complementary serum biomarkers to differentiate prostate cancer from benign prostatic hyperplasia using gel‐ and lectin‐based proteomics analyses</title><title>Electrophoresis</title><addtitle>Electrophoresis</addtitle><description>Diagnosis of prostate cancer (PCa) is currently much reliant on the invasive and time‐consuming transrectal ultrasound‐guided biopsy of the prostate gland, particularly in light of the inefficient use of prostate‐specific antigen as its biomarker. In the present study, we have profiled the sera of patients with PCa and benign prostatic hyperplasia (BPH) using the gel‐ and lectin‐based proteomics methods and demonstrated the significant differential expression of apolipoprotein AII, complement C3 beta chain fragment, inter‐alpha‐trypsin inhibitor heavy chain 4 fragment, transthyretin, alpha‐1‐antitrypsin, and high molecular weight kininogen (light chain) between the two groups of patients’ samples. Our data are suggestive of the potential use of the serum proteins as complementary biomarkers to effectively discriminate PCa from BPH, although this requires further extensive validation on clinically representative populations.</description><subject>Aged</subject><subject>Apolipoprotein A-II</subject><subject>Benign</subject><subject>Benign prostatic hyperplasia</subject><subject>Biomarker</subject><subject>biomarkers</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biomarkers, Tumor - chemistry</subject><subject>Biopsy</subject><subject>Blood Proteins - analysis</subject><subject>Blood Proteins - chemistry</subject><subject>Blood Proteins - metabolism</subject><subject>Complement component C3</subject><subject>Data processing</subject><subject>Diagnosis, Differential</subject><subject>Electrophoresis, Gel, Two-Dimensional</subject><subject>Glycoproteins - blood</subject><subject>Glycoproteins - chemistry</subject><subject>Glycoproteins - metabolism</subject><subject>Humans</subject><subject>Hyperplasia</subject><subject>Invasiveness</subject><subject>kininogens</subject><subject>Lectin</subject><subject>Lectins - metabolism</subject><subject>Light chains</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prostate cancer</subject><subject>prostate-specific antigen</subject><subject>Prostatic Hyperplasia - blood</subject><subject>Prostatic Neoplasms - blood</subject><subject>Proteomics</subject><subject>Proteomics - methods</subject><subject>Serum proteins</subject><subject>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</subject><subject>Therapeutic applications</subject><subject>transthyretin</subject><issn>0173-0835</issn><issn>1862-8346</issn><issn>1522-2683</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNqFkc1u1DAUhS0EokNhyxJ5ySaD_xI7S1QVWmkkkIB15NjXg8GJg52oyo5H4FX6SjwJDtN225V9fb9zZJ2D0GtK9pQQ9g7ClPeM0DI0RD1BO1ozVrFG8adoR6jkFVG8PkMvcv5BCBGtEM_RGWNSECHFDt1eWxhn77zRs48jjg5Pcd6edMAmDlOAoUw6rThDWgbc-zjo9BNSxnPE1jsH6T8-A55SzPN2MXo0kLBLsQhg9MfxfucN_r5OkKags9d4yX484iOEv7__YD1aHMDMfixTrzPYTTVDHLzJZavDmiG_RM-cDhle3Z3n6NuHy68XV9Xh08fri_eHynCmVGUaaZnSsgYLDe1V35DWidq4njFay5ZqyRRlljZaS2KooRysJpYJVwtoJD9Hb0--5Q-_FshzN_hsIAQ9QlxyR5ksKVKh1OMoYUzxtlWb6_6EmpJHTuC6KfkS6Fqgbmu02xrtHhotgjd33ks_gH3A7yssgDgBNz7A-ohdd3n4_EUwrvg_G4qzoA</recordid><startdate>201207</startdate><enddate>201207</enddate><creator>Jayapalan, Jaime J.</creator><creator>Ng, Keng L.</creator><creator>Razack, Azad H. A.</creator><creator>Hashim, Onn H.</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>201207</creationdate><title>Identification of potential complementary serum biomarkers to differentiate prostate cancer from benign prostatic hyperplasia using gel‐ and lectin‐based proteomics analyses</title><author>Jayapalan, Jaime J. ; Ng, Keng L. ; Razack, Azad H. A. ; Hashim, Onn H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3288-c67d28a75ede61b8b609f45cfb2215791a72812d16aa70c1c13eda0d24f54e673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Aged</topic><topic>Apolipoprotein A-II</topic><topic>Benign</topic><topic>Benign prostatic hyperplasia</topic><topic>Biomarker</topic><topic>biomarkers</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biomarkers, Tumor - chemistry</topic><topic>Biopsy</topic><topic>Blood Proteins - analysis</topic><topic>Blood Proteins - chemistry</topic><topic>Blood Proteins - metabolism</topic><topic>Complement component C3</topic><topic>Data processing</topic><topic>Diagnosis, Differential</topic><topic>Electrophoresis, Gel, Two-Dimensional</topic><topic>Glycoproteins - blood</topic><topic>Glycoproteins - chemistry</topic><topic>Glycoproteins - metabolism</topic><topic>Humans</topic><topic>Hyperplasia</topic><topic>Invasiveness</topic><topic>kininogens</topic><topic>Lectin</topic><topic>Lectins - metabolism</topic><topic>Light chains</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prostate cancer</topic><topic>prostate-specific antigen</topic><topic>Prostatic Hyperplasia - blood</topic><topic>Prostatic Neoplasms - blood</topic><topic>Proteomics</topic><topic>Proteomics - methods</topic><topic>Serum proteins</topic><topic>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</topic><topic>Therapeutic applications</topic><topic>transthyretin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jayapalan, Jaime J.</creatorcontrib><creatorcontrib>Ng, Keng L.</creatorcontrib><creatorcontrib>Razack, Azad H. A.</creatorcontrib><creatorcontrib>Hashim, Onn H.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Electrophoresis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jayapalan, Jaime J.</au><au>Ng, Keng L.</au><au>Razack, Azad H. A.</au><au>Hashim, Onn H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Identification of potential complementary serum biomarkers to differentiate prostate cancer from benign prostatic hyperplasia using gel‐ and lectin‐based proteomics analyses</atitle><jtitle>Electrophoresis</jtitle><addtitle>Electrophoresis</addtitle><date>2012-07</date><risdate>2012</risdate><volume>33</volume><issue>12</issue><spage>1855</spage><epage>1862</epage><pages>1855-1862</pages><issn>0173-0835</issn><issn>1862-8346</issn><eissn>1522-2683</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><notes>ObjectType-Article-2</notes><notes>ObjectType-Feature-1</notes><abstract>Diagnosis of prostate cancer (PCa) is currently much reliant on the invasive and time‐consuming transrectal ultrasound‐guided biopsy of the prostate gland, particularly in light of the inefficient use of prostate‐specific antigen as its biomarker. In the present study, we have profiled the sera of patients with PCa and benign prostatic hyperplasia (BPH) using the gel‐ and lectin‐based proteomics methods and demonstrated the significant differential expression of apolipoprotein AII, complement C3 beta chain fragment, inter‐alpha‐trypsin inhibitor heavy chain 4 fragment, transthyretin, alpha‐1‐antitrypsin, and high molecular weight kininogen (light chain) between the two groups of patients’ samples. Our data are suggestive of the potential use of the serum proteins as complementary biomarkers to effectively discriminate PCa from BPH, although this requires further extensive validation on clinically representative populations.</abstract><cop>Germany</cop><pmid>22740474</pmid><doi>10.1002/elps.201100608</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0173-0835 |
| ispartof | Electrophoresis, 2012-07, Vol.33 (12), p.1855-1862 |
| issn | 0173-0835 1862-8346 1522-2683 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1272741488 |
| source | Wiley |
| subjects | Aged Apolipoprotein A-II Benign Benign prostatic hyperplasia Biomarker biomarkers Biomarkers, Tumor - blood Biomarkers, Tumor - chemistry Biopsy Blood Proteins - analysis Blood Proteins - chemistry Blood Proteins - metabolism Complement component C3 Data processing Diagnosis, Differential Electrophoresis, Gel, Two-Dimensional Glycoproteins - blood Glycoproteins - chemistry Glycoproteins - metabolism Humans Hyperplasia Invasiveness kininogens Lectin Lectins - metabolism Light chains Male Middle Aged Prostate cancer prostate-specific antigen Prostatic Hyperplasia - blood Prostatic Neoplasms - blood Proteomics Proteomics - methods Serum proteins Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization Therapeutic applications transthyretin |
| title | Identification of potential complementary serum biomarkers to differentiate prostate cancer from benign prostatic hyperplasia using gel‐ and lectin‐based proteomics analyses |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T12%3A25%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Identification%20of%20potential%20complementary%20serum%20biomarkers%20to%20differentiate%20prostate%20cancer%20from%20benign%20prostatic%20hyperplasia%20using%20gel%E2%80%90%20and%20lectin%E2%80%90based%20proteomics%20analyses&rft.jtitle=Electrophoresis&rft.au=Jayapalan,%20Jaime%20J.&rft.date=2012-07&rft.volume=33&rft.issue=12&rft.spage=1855&rft.epage=1862&rft.pages=1855-1862&rft.issn=0173-0835&rft.eissn=1522-2683&rft_id=info:doi/10.1002/elps.201100608&rft_dat=%3Cproquest_cross%3E1272741488%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3288-c67d28a75ede61b8b609f45cfb2215791a72812d16aa70c1c13eda0d24f54e673%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1022839987&rft_id=info:pmid/22740474&rfr_iscdi=true |